Objective This study compared the effectiveness and safety of radiofrequency ablation (RFA) and microwave ablation (MWA) for primary hyperparathyroidism (pHPT), evaluating biochemical outcomes, cure rates, recurrence, complications, and symptom improvement. Materials and methods A retrospective analysis included pHPT patients treated with RFA or MWA from January 2014 to November 2022. We assessed parathyroid hormone (PTH) and serum calcium levels pre- and post-ablation, alongside clinical symptoms (bone pain, fatigue, kidney stones). Cure was defined as sustained PTH (12–88 pg/mL) and calcium (2.2–2.65 mmol/L) normalization for ≥ 6 months. Results Sixty-nine patients (mean age: 54.5 ± 13.3 years) were analyzed: 48 received MWA, 21 RFA. Both groups showed significant PTH and calcium reductions post-ablation (p < 0.01). The 6-month cure rate was 81.2% (MWA: 83.3%, RFA: 76.2%, p = 0.57). Recurrence occurred in 18.8% of patients, primarily within 6–12 months. Pre-ablation PTH ≥ 176 pg/mL strongly predicted recurrence (HR: 2.86, p = 0.005). Post-ablation PTH at 10 and 20 min predicted 2-year outcomes. Symptom improvement was notable: 60% of bone pain and 50% of fatigue cases improved significantly (p < 0.05). No new kidney stones were reported. Minor complications included transient hoarseness (54.4%) and minor hemorrhage (10.1%); no major or delayed complications, such as thyroid dysfunction, occurred. Conclusion RFA and MWA are equally effective and safe for pHPT, offering comparable cure and recurrence rates, significant symptom relief, and minimal complications. Elevated pre-ablation PTH signals a higher recurrence risk, with early post-ablation PTH predictive of long-term success. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> What are the long-term efficacy, safety, and clinical benefits of radiofrequency and microwave ablation for primary hyperparathyroidism, particularly regarding cure rates, recurrence risks, and symptom improvement? <Emphasis Type="BoldItalic">Findings</Emphasis> Radiofrequency and microwave ablation achieved an 81.2% cure rate, significant symptom improvement, with minimal complications; 18.8% recurrence was linked to high baseline PTH. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> Thermal ablation offers a minimally invasive, safe alternative to surgery for primary hyperparathyroidism, with high cure rates, low complication risks, and significant symptom relief, suitable for patients unfit for or preferring to avoid surgical intervention. Graphical Abstract

Thermal ablation for primary hyperparathyroidism: long-term follow-up results

期刊论文
发表日期：

2025年11月21日

查看全文

RunZhe Wang,
Xiao Yang,
FeiHong Yu,
BoQiang Fan

摘要

Objective

This study compared the effectiveness and safety of radiofrequency ablation (RFA) and microwave ablation (MWA) for primary hyperparathyroidism (pHPT), evaluating biochemical outcomes, cure rates, recurrence, complications, and symptom improvement.

Materials and methods

A retrospective analysis included pHPT patients treated with RFA or MWA from January 2014 to November 2022. We assessed parathyroid hormone (PTH) and serum calcium levels pre- and post-ablation, alongside clinical symptoms (bone pain, fatigue, kidney stones). Cure was defined as sustained PTH (12–88 pg/mL) and calcium (2.2–2.65 mmol/L) normalization for ≥ 6 months.

Results

Sixty-nine patients (mean age: 54.5 ± 13.3 years) were analyzed: 48 received MWA, 21 RFA. Both groups showed significant PTH and calcium reductions post-ablation (p < 0.01). The 6-month cure rate was 81.2% (MWA: 83.3%, RFA: 76.2%, p = 0.57). Recurrence occurred in 18.8% of patients, primarily within 6–12 months. Pre-ablation PTH ≥ 176 pg/mL strongly predicted recurrence (HR: 2.86, p = 0.005). Post-ablation PTH at 10 and 20 min predicted 2-year outcomes. Symptom improvement was notable: 60% of bone pain and 50% of fatigue cases improved significantly (p < 0.05). No new kidney stones were reported. Minor complications included transient hoarseness (54.4%) and minor hemorrhage (10.1%); no major or delayed complications, such as thyroid dysfunction, occurred.

Conclusion

RFA and MWA are equally effective and safe for pHPT, offering comparable cure and recurrence rates, significant symptom relief, and minimal complications. Elevated pre-ablation PTH signals a higher recurrence risk, with early post-ablation PTH predictive of long-term success.

Key Points

Question What are the long-term efficacy, safety, and clinical benefits of radiofrequency and microwave ablation for primary hyperparathyroidism, particularly regarding cure rates, recurrence risks, and symptom improvement?

Findings Radiofrequency and microwave ablation achieved an 81.2% cure rate, significant symptom improvement, with minimal complications; 18.8% recurrence was linked to high baseline PTH.

Clinical relevance Thermal ablation offers a minimally invasive, safe alternative to surgery for primary hyperparathyroidism, with high cure rates, low complication risks, and significant symptom relief, suitable for patients unfit for or preferring to avoid surgical intervention.

Graphical Abstract